Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4529MR)

This product GTTS-WQ4529MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4529MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10695MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ9102MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ834MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ6849MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ6480MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ10720MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ5410MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW